BlackRock Group LTD Buys 65,626 Shares of AveXis, Inc. (AVXS)
BlackRock Group LTD boosted its position in shares of AveXis, Inc. (NASDAQ:AVXS) by 59.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 176,526 shares of the company’s stock after buying an additional 65,626 shares during the period. BlackRock Group LTD’s holdings in AveXis were worth $7,274,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the stock. Alliancebernstein L.P. bought a new position in shares of AveXis during the second quarter worth approximately $532,000. BlackRock Institutional Trust Company N.A. raised its position in shares of AveXis by 11.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 41,986 shares of the company’s stock worth $1,596,000 after buying an additional 4,407 shares during the period. BlackRock Inc. raised its position in shares of AveXis by 46.9% in the second quarter. BlackRock Inc. now owns 30,386 shares of the company’s stock worth $1,155,000 after buying an additional 9,700 shares during the period. BlackRock Investment Management LLC raised its position in shares of AveXis by 8.3% in the second quarter. BlackRock Investment Management LLC now owns 33,303 shares of the company’s stock worth $1,266,000 after buying an additional 2,553 shares during the period. Finally, BlackRock Advisors LLC raised its position in shares of AveXis by 26.8% in the second quarter. BlackRock Advisors LLC now owns 281,525 shares of the company’s stock worth $10,704,000 after buying an additional 59,504 shares during the period. 68.23% of the stock is currently owned by institutional investors.
AveXis, Inc. (NASDAQ:AVXS) opened at 52.61 on Friday. The firm’s 50 day moving average is $53.40 and its 200-day moving average is $45.50. The firm’s market cap is $1.46 billion. AveXis, Inc. has a 12 month low of $16.11 and a 12 month high of $72.72.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.18. On average, equities analysts forecast that AveXis, Inc. will post ($3.51) EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The legal version of this piece of content can be viewed at http://www.dailypolitical.com/2017/01/14/blackrock-group-ltd-buys-65626-shares-of-avexis-inc-avxs.html.
AVXS has been the topic of a number of research reports. Bank of America Corporation initiated coverage on shares of AveXis in a research note on Friday, October 21st. They issued a “buy” rating on the stock. Zacks Investment Research upgraded shares of AveXis from a “hold” rating to a “buy” rating and set a $52.00 price target on the stock in a research note on Tuesday, October 25th. Jefferies Group upped their price target on shares of AveXis from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, October 12th. BMO Capital Markets reiterated an “outperform” rating and issued a $52.00 price target on shares of AveXis in a research note on Monday, October 10th. Finally, Chardan Capital set a $85.00 price target on shares of AveXis and gave the company a “buy” rating in a research note on Wednesday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. AveXis currently has an average rating of “Buy” and an average price target of $67.72.
AveXis Company Profile
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.